-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
通榆县|
阿尔山市|
墨竹工卡县|
永修县|
包头市|
台东市|
泸溪县|
怀仁县|
龙里县|
广德县|
连南|
高唐县|
台南市|
邓州市|
囊谦县|
丰城市|
哈巴河县|
福清市|
平南县|
大港区|
五河县|
鲁甸县|
吴桥县|
舒城县|
富民县|
墨玉县|
图们市|
上饶县|
鹤峰县|
佛坪县|
车致|
和林格尔县|
沂源县|
天门市|
遂溪县|
梧州市|
四川省|
綦江县|
攀枝花市|
台湾省|
健康|